-
Stable Yeast Expression of Exendin-4 for Diabetes Research
2026-08-29
The 2024 Frontiers in Systems Biology study evaluated recombinant Exendin-4 production in Escherichia coli and Saccharomyces cerevisiae, with the strongest validation obtained from a chromosomally integrated yeast strain. Detection at the expected peptide size and confirmation by immunoassay establish a foundation for investigating locally propagated production systems, while leaving purification, bioactivity, dosage, safety, and therapeutic performance for future work.
-
DFCP1 Regulates ATGL-Driven Lipid Droplet Lipolysis
2026-08-28
The reference study identifies DFCP1/ZFYVE1 as a nutrient-sensitive regulator of starvation-induced lipid droplet catabolism. Its central finding is that DFCP1 recruits ATGL to lipid droplets while limiting ATGL dissociation, revealing a direct mechanism that modulates lipolysis independently of previously recognized ATGL regulators.
-
Clathrin-Mediated Entry of Grass Carp Reovirus
2026-08-28
Wang et al. used complementary pharmacological, ultrastructural, and molecular assays to show that genotype III grass carp reovirus enters fish kidney cells through a dynamin-dependent, clathrin-mediated pathway that requires endosomal acidification. The study provides a useful mechanistic framework for endocytosis research while emphasizing that inhibitor-based pathway assignments require controls for compound specificity, toxicity, and effects on post-entry replication.
-
SAR131675: VEGFR-3 Inhibitor Workflow
2026-08-27
SAR131675 is a selective VEGFR-3 inhibitor for separating lymphatic signaling from broader VEGF-receptor effects. This workflow connects biochemical kinase assays, endothelial phenotyping, and the newly reported hepatocyte–macrophage axis in hepatic fibrosis research.
-
Bestatin (Ubenimex) Experimental Workflows
2026-08-27
Build more interpretable aminopeptidase, apoptosis, and multidrug-resistance experiments with Bestatin (Ubenimex), using concentration-aware workflows and DMSO controls. This guide connects biochemical inhibition to cancer-cell assays while emphasizing selectivity, fresh-solution handling, and troubleshooting.
-
USP7–PKM2 Metabolic Control in Acute Pancreatitis
2026-08-26
The 2025 Cell Death and Disease study identifies USP7 as an upstream regulator of PKM2-dependent metabolic reprogramming and macrophage polarization in severe acute pancreatitis. Its combination of genetic manipulation, metabolic flux analysis, protein-interaction assays, and pharmacological rescue links deubiquitination of PKM2 to inflammatory disease severity and provides a framework for testing PKM2-centered interventions.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-08-26
A 2026 FASEB Journal study developed chemically modified p21 mRNA in lipid nanoparticles for localized intravesical treatment of bladder cancer. The preclinical strategy restored nuclear p21, disrupted cell-cycle progression, induced DNA-damage signaling and apoptosis, and suppressed orthotopic tumor growth while limiting systemic exposure.
-
LRG1 and Neutrophil Mitochondria in Bladder Cancer
2026-08-25
This Advanced Science study identifies a tumor-derived LRG1–neutrophil signaling axis that disrupts mitochondrial homeostasis, promotes NETosis, and destabilizes bladder-cancer vasculature. Its integrated single-cell, animal-model, biochemical, and clinical analyses suggest that limiting this pathway may normalize vessels and improve responses to cisplatin and anti-PD-1 therapy.
-
Bestatin (Ubenimex) Workflows for Protease Research
2026-08-25
Bestatin (Ubenimex) provides a selective chemical entry point for aminopeptidase activity measurement, MDR research, and mechanism-focused cancer research. This guide combines practical formulation and assay workflows with a carefully bounded translation of viral necroptosis findings into experimental design choices.
-
Brefeldin A: From Trafficking to Translation
2026-08-24
Brefeldin A (BFA) is more than a vesicle transport inhibitor: it is a mechanistic probe for connecting ER-to-Golgi blockade with ER stress, cytoskeletal remodeling, apoptosis, and potentially endothelial barrier biology. This thought-leadership framework shows how translational researchers can use BFA with appropriate controls, evidence boundaries, and biomarker-oriented readouts.
-
Solanesol B8776: Practical Research Workflow
2026-08-24
Solanesol (B8776) provides a defined polyisoprenoid alcohol for hydrophobic biochemical, membrane-related, and exploratory enzyme or cell-based workflows. Its limited solubility requires DMSO-based stock preparation; it is insoluble in water and ethanol and is not intended for diagnostic, clinical, or medical use.
-
Central Opioid Circuits in Mechanical Hypersensitivity
2026-08-23
Yin et al. identify a brain-to-spinal μ-opioid circuit linking the lateral parabrachial nucleus, hypothalamic dynorphin neurons, and spinal dorsal horn GABAergic cells to morphine-induced mechanical hypersensitivity and analgesic tolerance. The study reframes these adverse effects as failures of central mechanical-pain gating and provides a circuit-level framework for testing receptor-specific interventions.
-
SN-38 Disrupts FUBP1–FUSE Binding
2026-08-22
The reference study identifies an additional action of camptothecin and SN-38: inhibition of the FUBP1 interaction with the single-stranded DNA element FUSE. By linking topoisomerase I inhibitor activity to transcriptional deregulation in hepatocellular carcinoma cells, the work provides a mechanistic basis for studying FUBP1 dependence in cancer models.
-
Rucaparib in DNA Damage Response Workflows
2026-08-22
Rucaparib (AG-014699) helps researchers connect PARP1 inhibition with persistent DNA damage, radiosensitization, and repair-deficient cancer phenotypes. This practical guide shows how to build, control, and troubleshoot assays that distinguish DNA repair failure from transcription-linked cell death.
-
MK-571: Reproducible Assay Design
2026-08-21
This scenario-based guide explains how MK-571 (L-660,711) can improve interpretation of cell viability, proliferation, and cytotoxicity experiments involving leukotriene signaling or MRP1 activity. It covers formulation, controls, protocol handling, mechanistic confounders, and vendor-selection considerations for SKU B7023.